Our data suggest that HSP90β promotes the growth and sorafenib resistance of HCC cells by suppressing STUB1‐induced YTHDF2 ubiquitination and degradation, which could inaugurate a novel intervention strategy for the clinical treatment of HCC. Here, YTHDF2 is linked to hepatocellular carcinoma.